A detailed history of Baker Ellis Asset Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baker Ellis Asset Management LLC holds 1,058 shares of VRTX stock, worth $446,476. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,058
Previous 738 43.36%
Holding current value
$446,476
Previous $343,000 24.2%
% of portfolio
0.06%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

BUY
$396.64 - $516.74 $126,924 - $165,356
320 Added 43.36%
1,058 $426,000
Q3 2024

Oct 15, 2024

SELL
$460.0 - $505.78 $14,720 - $16,184
-32 Reduced 4.16%
738 $343,000
Q2 2024

Jul 09, 2024

BUY
$392.81 - $485.53 $62,849 - $77,684
160 Added 26.23%
770 $360,000
Q1 2024

Apr 17, 2024

BUY
$407.69 - $446.08 $248,690 - $272,108
610 New
610 $254,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $108B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Baker Ellis Asset Management LLC Portfolio

Follow Baker Ellis Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Ellis Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baker Ellis Asset Management LLC with notifications on news.